|
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
However, miR-122-5p, -192-5p, -34a-5p and -22-3p demonstrated a much more significant induction in patients with hepatocellular DILI, thus revealing better specificity for hepatocellular damage.
|
31198949 |
2020 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These data suggest that C/EBPα and eEF1A1 may play opposing roles in Sp1-regulating miR-122 transcription, and the eEF1A1 upregulation accompanied by C/EBPα downregulation in HCC may switch the regulatory functions of Sp1 and led to reduced miR-122 transcription.
|
31561740 |
2020 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MiR-122 was reduced in hepatocarcinoma tissues compared to the para-carcinoma tissues, which was relatively low or high in hepatocarcinoma cell line SMMC7721 or Hep3B, and over-expressed miR-122 inhibited proliferation, migration or invasion in hepatocarcinoma cells.
|
31558184 |
2020 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Both down-regulation of miR-122 and up-regulation of TLR4 were found to be correlated with low overall survival rate of HCC patients.
|
31477445 |
2020 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hepatocellular carcinoma-bearing mice were injected intratumorally with microRNA-122 (miR-122) mimics and an miR-122 negative control in the treatment and control groups, respectively.
|
31225651 |
2020 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study demonstrated, for the first time, that ADAR1 plays an antiviral role against HBV infection by increasing the level of miRNA-122 in hepatocytes.
|
31366735 |
2019 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
When correlating miRNA expression with clinical parameters we detected significant association between hepatitis B virus (HBV) infection and miR-122 in serum as well as several serum and tissue-miRNAs that correlated with surgery type.
|
31660891 |
2019 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, the researches on the accuracy of miR122 detection in chronic viral hepatitis have been inconsistent, leading us to conduct this meta-analysis to systematically summarize the diagnostic value of circulating miR-122 in patients with hepatitis B virus (HBV) and/or hepatitis C virus (HCV)-associated chronic viral hepatitis.<b>Methods:</b> A comprehensive literature search (updated to January 30, 2019) in PubMed, Cochrane library, EMBASE, CNKI, Wanfang, and CQVIP databases was performed to identify eligible studies.
|
31427483 |
2019 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Collectively, the findings of the present study may provide insight into the mechanistic role of HBV infection in modulating the expression of miR‑122, which targets the 3'UTR of APOBEC2 mRNA, subsequently inducing liver carcinogenesis.
|
31485598 |
2019 |
|
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Conclusion: GLDH appears to be more useful than miR-122 in identifying DILI patients, and K18, OPN, and MCSFR are promising candidates for prediction of prognosis during an acute DILI event.
|
29357190 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The strategy developed herein is thus a highly promising platform for an effective codelivery of miRNA-122 and 5-Fu with facile fabrication and great potential for the clinical translation toward HCC synergistic therapy.
|
30802029 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Diagnostic Performance of microRNA-122 and microRNA-224 in Hepatitis C Virus-Induced Hepatocellular Carcinoma (HCC).
|
31450927 |
2019 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
However, the expression level of miR-122 in blood did not have the ability in predicting OS (HR = 0.75, 95% CI 0.44-1.28, P = .29) and PFS (HR = 0.84, 95% CI 0.58-1.20, P = .33) of HCC.
|
30921182 |
2019 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
High expression of LINC01551 and ADAM10 yet low-expression of miR-122-5p were revealed in HCC tissues and cells.
|
31270840 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Emerging therapeutic approaches targeting miR-122 could be applicable in patients with miR-122 downregulated hepatocellular carcinoma.
|
31611609 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A panel consisting of miRNA-122-5p + miRNA-486-5p + miRNA-142-3p distinguished HCC from cirrhosis (AUC = 0.94; sensitivity = 80%, specificity = 95%; <i>p</i> < 0.001), outperforming AFP (AUC = 0.64, <i>p</i> = 0.065).
|
30781550 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results suggest that serum miR-122 might serve as a novel and potential noninvasive biomarker for HCV-induced HCC.
|
31749873 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, the combination of the miRNA-122 and a fetoprotein may further improve the diagnostic accuracy between the HCC and healthy groups (area under the curve, 0.980; 95% confidence interval, 0.958-1.000).
|
30881509 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Infusions of miR-122 and, possibly, some other miRNAs may be efficient for preventing NAFLD-associated hepatocellular carcinoma.
|
30248223 |
2019 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We found that the expression of miR-122 was decreased in HCC tissues and showed the diagnostic capacity for HCC in TCGA datasets.
|
31340754 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this work, with the use of newly developed PEGylated biodegradable charged polyester-based vectors (PEG-BCPVs) as the carrier, the miR26a and miR122 codelivering therapeutic strategy (PEG-BCPVs/miR26a/miR122 as the delivery formulation) is successfully developed for efficient treatment of human hepatocellular carcinoma (HCC).
|
30829008 |
2019 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In an HCC rat model, high miR-122 levels were associated with negative SerpinB3 expression, while low miR-122 levels correlated with SerpinB3 positivity.
|
30717317 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, miR-122 could serve as a novel potential therapeutic target for HCC.
|
30539797 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
An inverse correlation between LINC00205 and miR-122-5p was detected in HCC tissues.
|
31272761 |
2019 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, there was a significant correlation between serum miR-122 levels and the levels of HBV DNA, hepatitis B e-antigen, and HBV core-related antigen.
|
29896794 |
2018 |